Breyanzi
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Sales of the CAR T-cell therapy continue to grow helped by BMS's expansion of its cell manufacturing facilities.
FDA Approves Bristol Myers Squibb's Breyanzi in Mantle Cell Lymphoma
The approval comes after BMS nabbed FDA accelerated approval for the CAR T-cell therapy in follicular lymphoma earlier this month.
Bristol Myers Squibb Nabs FDA Accelerated Approval for Breyanzi in Follicular Lymphoma
The agency approved the autologous CAR T-cell therapy after around 96 percent of patients in the Phase II TRANSCEND-FL trial responded to it.
Amid a $1.5 billion cost-savings plan, BMS is focusing on advancing porfolio products that can grow revenues and help diversify its assets.